{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:14:27Z","timestamp":1790691267932,"version":"4.1.0"},"reference-count":60,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"abstract":"<jats:p>Objective. The objective was to assess the cardiac effects of growth hormone (GH) therapy. Anthracycline-treated childhood cancer survivors frequently have reduced left ventricular (LV) wall thickness and contractility, and GH therapy may affect these factors.<\/jats:p>\n               <jats:p>Methods. We examined serial cardiac findings for 34 anthracycline-treated childhood cancer survivors with several years of GH therapy and baseline cardiac z scores similar to those of a comparison group (86 similar cancer survivors without GH therapy).<\/jats:p>\n               <jats:p>Results. LV contractility was decreased among GH-treated patients before, during, and after GH therapy (\u22121.08 SD below the age-adjusted population mean before therapy and \u22121.88 SD 4 years after therapy ceased, with each value depressed below normal). Contractility was higher in the control group than in the GH-treated group, with this difference being nearly significant. The GH-treated children had thinner LV walls before GH therapy (\u22121.38 SD). Wall thickness increased during GH therapy (from \u22121.38 SD to \u22121.09 SD after 3 years of GH therapy), but the effect was lost shortly after GH therapy ended and thickness diminished over time (\u22121.50 SD at 1 year after therapy and \u22121.96 SD at 4 years). During GH therapy, the wall thickness for the GH-treated group was greater than that for the control group; however, by 4 years after therapy, there was no difference between the GH-treated group and the control group.<\/jats:p>\n               <jats:p>Conclusions. GH therapy among anthracycline-treated survivors of childhood cancer increased LV wall thickness, but the effect was lost after therapy was discontinued. The therapy did not affect the progressive LV dysfunction.<\/jats:p>","DOI":"10.1542\/peds.2004-1004","type":"journal-article","created":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T17:19:46Z","timestamp":1117646386000},"page":"1613-1622","source":"Crossref","is-referenced-by-count":63,"title":["Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines"],"prefix":"10.1542","volume":"115","author":[{"given":"Steven E.","family":"Lipshultz","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Miller School of Medicine at the University of Miami, Holtz Children's Hospital of the University of Miami-Jackson Memorial Medical Center, and the Sylvester Comprehensive Cancer Center, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Vlach","sequence":"additional","affiliation":[{"name":"Department of Cardiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart R.","family":"Lipsitz","sequence":"additional","affiliation":[{"name":"Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Children's Hospital, Boston, Massachusetts"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy L.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Cardiology and"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Colan","sequence":"additional","affiliation":[{"name":"Department of Cardiology and"},{"name":"Department of Pediatrics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"2021120819222856900_R1","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med.\u20081991;324:808\u2013815","DOI":"10.1056\/NEJM199103213241205"},{"key":"2021120819222856900_R2","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med.\u20081995;332:1738\u20131743","DOI":"10.1056\/NEJM199506293322602"},{"key":"2021120819222856900_R3","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629\u20132636","DOI":"10.1200\/JCO.2005.12.121"},{"key":"2021120819222856900_R4","unstructured":"Lipshultz SE, Colan SD, Sanders SP, Sallan SE. Cardiac mechanics after growth hormone therapy in pediatric Adriamycin recipients [abstract]. Pediatr Res.\u20081989;25:153A"},{"key":"2021120819222856900_R5","unstructured":"Oberfield SE, Sklar CA. Endocrine sequelae in survivors of childhood cancer. Adolesc Med.\u20082002;13:161\u2013170"},{"key":"2021120819222856900_R6","doi-asserted-by":"crossref","unstructured":"Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med.\u20081996;334:809\u2013814","DOI":"10.1056\/NEJM199603283341301"},{"key":"2021120819222856900_R7","doi-asserted-by":"crossref","unstructured":"Cuneo RC, Wilmshurst P, Lowy C, et al. Cardiac failure responding to growth hormone. Lancet.\u20081989;1:838\u2013839","DOI":"10.1016\/S0140-6736(89)92290-3"},{"key":"2021120819222856900_R8","doi-asserted-by":"crossref","unstructured":"Volterrani M, Desenzani P, Lorusso R, et al. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet.\u20081997;349:1067\u20131068","DOI":"10.1016\/S0140-6736(97)24015-8"},{"key":"2021120819222856900_R9","doi-asserted-by":"crossref","unstructured":"Yang R, Bunting S, Gillett N, et al. Growth hormone improves cardiac performance in experimental heart failure. Circulation.\u20081995;92:262\u2013267","DOI":"10.1161\/01.CIR.92.2.262"},{"key":"2021120819222856900_R10","doi-asserted-by":"crossref","unstructured":"Moran AM, Colan SD, Majzoub JA, Newberger JW. Exogenous growth hormone: a new therapy for dilated cardiomyopathy. Prog Pediatr Cardiol.\u20082000;12:125\u2013132","DOI":"10.1016\/S1058-9813(00)00064-3"},{"key":"2021120819222856900_R11","doi-asserted-by":"crossref","unstructured":"Mayoux E, Ventrua-Clapier R, Timsit J, et al. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res.\u20081993;72:57\u201364","DOI":"10.1161\/01.RES.72.1.57"},{"key":"2021120819222856900_R12","unstructured":"Thuesen L, Christiansen JS, Sorensen KE, et al. Increased myocardial contractility following growth hormone administration in normal man. Dan Med Bull.\u20081988;35:193\u2013196"},{"key":"2021120819222856900_R13","doi-asserted-by":"crossref","unstructured":"Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev.\u20081994;15:555\u2013573","DOI":"10.1210\/edrv-15-5-555"},{"key":"2021120819222856900_R14","doi-asserted-by":"crossref","unstructured":"Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-1 induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation.\u20081993;87:1715\u20131721","DOI":"10.1161\/01.CIR.87.5.1715"},{"key":"2021120819222856900_R15","doi-asserted-by":"crossref","unstructured":"Perrot A, Ranke MB, Dietz R, et al. Growth hormone treatment in dilated cardiomyopathy. J Card Surg.\u20082001;16:127\u2013131","DOI":"10.1111\/j.1540-8191.2001.tb00497.x"},{"key":"2021120819222856900_R16","doi-asserted-by":"crossref","unstructured":"Fazio S, Cittadini A, Sabatini D, et al. Growth hormone and heart performance: a novel mechanism of cardiac wall stress regulation in humans. Eur Heart J.\u20081997;18:340\u2013347","DOI":"10.1093\/oxfordjournals.eurheartj.a015237"},{"key":"2021120819222856900_R17","doi-asserted-by":"crossref","unstructured":"Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab.\u20081993;77:1671\u20131676","DOI":"10.1210\/jc.77.6.1671"},{"key":"2021120819222856900_R18","doi-asserted-by":"crossref","unstructured":"Cittadini A, Cuocolo A, Merola B, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol.\u20081994;267:E219\u2013E225","DOI":"10.1152\/ajpendo.1994.267.2.E219"},{"key":"2021120819222856900_R19","doi-asserted-by":"crossref","unstructured":"Merola B, Cittadini A, Colao A, et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab.\u20081993;77:1658\u20131661","DOI":"10.1210\/jcem.77.6.8263155"},{"key":"2021120819222856900_R20","doi-asserted-by":"crossref","unstructured":"Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc.\u20082003;78:1521\u20131526","DOI":"10.4065\/78.12.1521"},{"key":"2021120819222856900_R21","doi-asserted-by":"crossref","unstructured":"Osterziel KJ, Strohm O, Schuler J, et al. Randomized, double blind, placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet.\u20081998;351:1233\u20131237","DOI":"10.1016\/S0140-6736(97)11329-0"},{"key":"2021120819222856900_R22","doi-asserted-by":"crossref","unstructured":"Isgaard J, Bergh CH, Caidahl K, et al. A placebo controlled trial of human recombinant growth hormone in patients with congestive heart failure. Eur Heart J.\u20081998;19:1704\u20131711","DOI":"10.1053\/euhj.1998.1123"},{"key":"2021120819222856900_R23","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Easley K, Orav EJ, et al. The reliability of multicenter pediatric echocardiographic measurements of left ventricular structure and function. Circulation.\u20082001;104:310\u2013316","DOI":"10.1161\/01.CIR.104.3.310"},{"key":"2021120819222856900_R24","doi-asserted-by":"crossref","unstructured":"Colan SD, Parness IA, Spevak PJ, et al. Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol.\u20082002;19:619\u2013629","DOI":"10.1016\/S0735-1097(10)80282-7"},{"key":"2021120819222856900_R25","doi-asserted-by":"crossref","unstructured":"Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necroscopy findings. Am J Cardiol.\u20081986;57:450\u2013458","DOI":"10.1016\/0002-9149(86)90771-X"},{"key":"2021120819222856900_R26","doi-asserted-by":"crossref","unstructured":"Dibley MJ, Goldsby JB, Staehling NW, et al. Development of normalized curves for the international growth reference: historical and technical considerations. Am J Clin Nutr.\u20081987;46:736\u2013748","DOI":"10.1093\/ajcn\/46.5.736"},{"key":"2021120819222856900_R27","doi-asserted-by":"crossref","unstructured":"Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Gelber R, Lipshultz SE. Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics.\u20082002;58:621\u2013630","DOI":"10.1111\/j.0006-341X.2002.00621.x"},{"key":"2021120819222856900_R28","doi-asserted-by":"crossref","unstructured":"Houck WV, Pan LC, Kribbs SB, et al. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with development of congestive heart failure. Circulation.\u20081999;100:2003\u20132009","DOI":"10.1161\/01.CIR.100.19.2003"},{"key":"2021120819222856900_R29","doi-asserted-by":"crossref","unstructured":"Bruel A, Oxlund H, Nyengaard JR. Growth hormone increases the total number of myocyte nuclei in the left ventricle of adult rats. Growth Horm IGF Res.\u20082002;12:106\u2013115","DOI":"10.1054\/ghir.2002.0269"},{"key":"2021120819222856900_R30","doi-asserted-by":"crossref","unstructured":"Bruel A, Oxlund H, Nyengaard JR. Growth hormone increases the total number of cardiac myocyte nuclei in young rats but not in old rats. Mech Ageing Dev.\u20082002;123:1353\u20131362","DOI":"10.1016\/S0047-6374(02)00073-8"},{"key":"2021120819222856900_R31","doi-asserted-by":"crossref","unstructured":"Napoli R, Guardasole V, Matarazzo M, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol.\u20082002;39:90\u201395","DOI":"10.1016\/S0735-1097(01)01707-7"},{"key":"2021120819222856900_R32","doi-asserted-by":"crossref","unstructured":"Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation.\u20082003;108:2648\u20132652","DOI":"10.1161\/01.CIR.0000100720.01867.1D"},{"key":"2021120819222856900_R33","doi-asserted-by":"crossref","unstructured":"Shulman DI, Root AW, Diamond FB, Bereu BB, Martinez R, Boucek RJ Jr. Effects of one year of recombinant human growth hormone (GH) therapy on cardiac mass and function in children with classical GH deficiency. J Clin Endocrinol Metab.\u20082003;88:4095\u20134099","DOI":"10.1210\/jc.2003-030030"},{"key":"2021120819222856900_R34","doi-asserted-by":"crossref","unstructured":"Salerno M, Esposito V, Spinelli L, et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol (Oxf).\u20082004;60:630\u2013636","DOI":"10.1111\/j.1365-2265.2004.02026.x"},{"key":"2021120819222856900_R35","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol.\u20082004;22:769\u2013773","DOI":"10.1200\/JCO.2004.12.937"},{"key":"2021120819222856900_R36","doi-asserted-by":"crossref","unstructured":"Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol.\u20082004;22:3139\u20133148","DOI":"10.1200\/JCO.2004.09.109"},{"key":"2021120819222856900_R37","doi-asserted-by":"crossref","unstructured":"Adamopoulos S, Parissis JT, Paraskevaidis I, et al. Effect of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J.\u20082003;24:2186\u20132196","DOI":"10.1016\/S0195-668X(03)00480-9"},{"key":"2021120819222856900_R38","doi-asserted-by":"crossref","unstructured":"Acevedo M, Corbalan R, Chamorro G, et al. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol.\u20082003;87:185\u2013191","DOI":"10.1016\/S0167-5273(02)00249-8"},{"key":"2021120819222856900_R39","doi-asserted-by":"crossref","unstructured":"Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab.\u20082002;87:3650\u20133655","DOI":"10.1210\/jcem.87.8.8777"},{"key":"2021120819222856900_R40","doi-asserted-by":"crossref","unstructured":"Gurney JG, Ness KK, Stoval M, et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab.\u20082003;88:4731\u20134739","DOI":"10.1210\/jc.2003-030784"},{"key":"2021120819222856900_R41","doi-asserted-by":"crossref","unstructured":"Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer.\u20082003;97:663\u2013673","DOI":"10.1002\/cncr.11095"},{"key":"2021120819222856900_R42","doi-asserted-by":"crossref","unstructured":"Xu W, Janss A, Moshang T. Adult height and adult sitting height in childhood medulloblastoma survivors. J Clin Endocrinol Metab.\u20082003;88:4677\u20134681","DOI":"10.1210\/jc.2003-030619"},{"key":"2021120819222856900_R43","doi-asserted-by":"crossref","unstructured":"Gleeson HK, Stoeter R, Ogilvy-Stuart AL, Gattamaneni HR, Brennan BM, Shalet SM. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab.\u20082003;88:3682\u20133689","DOI":"10.1210\/jc.2003-030366"},{"key":"2021120819222856900_R44","doi-asserted-by":"crossref","unstructured":"Murray RD, Darzy KH, Gleeson HK, et al. GH-deficient survivors of childhood cancer: GH replacement during adult life. J Clin Endocrinol Metab.\u20082002;87:129\u2013135","DOI":"10.1210\/jcem.87.1.8146"},{"key":"2021120819222856900_R45","doi-asserted-by":"crossref","unstructured":"Jallad RS, Liberman B, Vianna CB, Viera ML, Ramires JA, Knoepfelmacher M. Effects of growth hormone replacement therapy on metabolic and cardiac parameters in adult patients with childhood-onset growth hormone deficiency. Growth Horm IGF Res.\u20082003;13:81\u201388","DOI":"10.1016\/S1096-6374(03)00006-6"},{"key":"2021120819222856900_R46","doi-asserted-by":"crossref","unstructured":"Feinberg MS, Scheinowitz M, Laron Z. Cardiac dimension and function in patients with childhood onset growth hormone deficiency, before and after growth hormone retreatment in adult age. Am Heart J.\u20082003;145:549\u2013553","DOI":"10.1067\/mhj.2003.175"},{"key":"2021120819222856900_R47","unstructured":"Lipshultz SE, Hinkle AS, French CA, et al. Accelerated atherosclerosis contributes to elevated global risk for premature symptomatic cardiovascular disease in survivors of childhood cancer. Proc Am Soc Clin Oncol.\u20082003;22:797"},{"key":"2021120819222856900_R48","doi-asserted-by":"crossref","unstructured":"Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med.\u20081999;341:785\u2013792","DOI":"10.1056\/NEJM199909093411102"},{"key":"2021120819222856900_R49","doi-asserted-by":"crossref","unstructured":"Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab.\u20082002;87:3136\u20133141","DOI":"10.1210\/jcem.87.7.8606"},{"key":"2021120819222856900_R50","doi-asserted-by":"crossref","unstructured":"Sperling MA, Saenger PH, Hintz R, et al. Growth hormone treatment and neoplasia: coincidence or consequence [editorial]?J Clin Endocrinol Metab.\u20082002;87:5351\u20135352","DOI":"10.1210\/jc.2002-021467"},{"key":"2021120819222856900_R51","doi-asserted-by":"crossref","unstructured":"Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959\u201385: a cohort study. Lancet.\u20082002;360:273\u2013277","DOI":"10.1016\/S0140-6736(02)09519-3"},{"key":"2021120819222856900_R52","doi-asserted-by":"crossref","unstructured":"Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary.\u20082002;5:21\u201325","DOI":"10.1023\/A:1022149300972"},{"key":"2021120819222856900_R53","doi-asserted-by":"crossref","unstructured":"Leung W, Rose SR, Zhou Y, et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol.\u20082002;20:2959\u20132964","DOI":"10.1200\/JCO.2002.09.142"},{"key":"2021120819222856900_R54","doi-asserted-by":"crossref","unstructured":"Kremer LC, van Dallen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol.\u20082001;19:191\u2013196","DOI":"10.1200\/JCO.2001.19.1.191"},{"key":"2021120819222856900_R55","doi-asserted-by":"crossref","unstructured":"Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol.\u20082001;19:1926\u20131934","DOI":"10.1200\/JCO.2001.19.7.1926"},{"key":"2021120819222856900_R56","doi-asserted-by":"crossref","unstructured":"Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol.\u20082001;19:3163\u20133172","DOI":"10.1200\/JCO.2001.19.13.3163"},{"key":"2021120819222856900_R57","doi-asserted-by":"crossref","unstructured":"Moller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol.\u20082001;19:3173\u20133181","DOI":"10.1200\/JCO.2001.19.13.3173"},{"key":"2021120819222856900_R58","doi-asserted-by":"crossref","unstructured":"Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol.\u20081999;17:3207\u20133215","DOI":"10.1200\/JCO.1999.17.10.3207"},{"key":"2021120819222856900_R59","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol.\u20082002;20:4517\u20134522","DOI":"10.1200\/JCO.2002.12.102"},{"key":"2021120819222856900_R60","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med.\u20082004;351:145\u2013153","DOI":"10.1056\/NEJMoa035153"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/6\/1613\/1027487\/zpe00605001613.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/6\/1613\/1027487\/zpe00605001613.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T20:22:02Z","timestamp":1638994922000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/6\/1613\/67457\/Cardiac-Changes-Associated-With-Growth-Hormone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":60,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,6,1]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-1004","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}